Physician profile
Hal W Brown
NPI 1902804677
$477,388.85
in general payments reported to CMS, 2019-2025
34 companies · $140K in 2025
The $140K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,063 · 2020: $1,487 · 2021: $273K · 2022: $27.00 · 2023: $234 · 2024: $60K · 2025: $140K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $140K · Grant: $60K · Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $140,000.00 |
| Grant | $60,000.00 |
| Food and Beverage | $537.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Swan Valley Medical Incorporated | $473,196.00 | 2021-2025 | |
| Amgen INC. | $452.80 | 2019-2021 | |
| Pfizer INC. | $445.36 | 2019-2020 | |
| Novo Nordisk INC | $409.49 | 2019-2023 | Wegovy |
| Glaxosmithkline, LLC. | $354.54 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $348.16 | 2019-2020 | |
| Amarin Pharma, INC. | $334.55 | 2019-2020 | |
| Boston Scientific Corporation | $217.52 | 2023-2025 | Watchman, Rezum Generator, Farapulse |
| Astrazeneca Pharmaceuticals Lp | $201.02 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $196.22 | 2019-2020 | |
| Daiichi Sankyo INC. | $190.48 | 2019-2020 | |
| Astellas Pharma US INC | $150.09 | 2019-2024 | Veozah |
| Lilly USA, LLC | $110.74 | 2019-2020 | |
| Allergan, INC. | $81.61 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.82 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $68.33 | 2020-2021 | |
| Sanofi Pasteur INC. | $54.40 | 2019 | |
| Eisai INC. | $50.08 | 2020 | |
| Tosoh Bioscience, INC. | $50.00 | 2019 | |
| Abbott Laboratories | $46.25 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $44.57 | 2019 | |
| Janssen Pharmaceuticals, INC | $40.81 | 2019 | |
| Abbvie INC. | $37.85 | 2024 | |
| Seqirus USA INC | $36.32 | 2019-2020 | |
| Esperion Therapeutics, INC. | $36.06 | 2020 | |
| Bioventus LLC | $24.58 | 2020 | |
| Roche Diagnostics Corporation | $20.06 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.61 | 2019 | |
| Vertiflex, INC. | $19.19 | 2019 | |
| Cvrx, INC. | $17.69 | 2023 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $17.63 | 2020 | |
| Genentech USA, INC. | $15.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.60 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$52,039.05 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hal Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.